Not finding it? Sign in to also search OpenAlex live.
-
PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer2023 Frontiers in Immunology article Medicine CAR-T cell therapy research Open access cited by 2 patents
Rosa A. van Amerongen, Sander Tuit, Anne K. Wouters, Marian van de Meent, Sterre L. Siekman, Miranda H. Meeuwsen, +9 more
25citations -
The implication of TET1, miR-200, and miR-494 expression with tumor formation in colorectal cancer: through targeting Wnt signaling2024 Molecular Biology Reports article Biochemistry, Genetics and Molecular Biology MicroRNA in disease regulation Open access
Raziye Tajali, Neda Zali, Fatemeh Naderi Noukabadi, Morteza Valinezhad, Farnaz Ghasemian, Makan Cheraghpour, +2 more
3citations -
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
Michael Lübbert, Pierre W. Wijermans, Michal Kiciński, Sylvain Chantepie, Walter J. F. M. van der Velden, Richard Noppeney, +32 more
41citations -
MPN-756: CPX-351 vs Standard of Care as Bridging to AlloHCT in Patients With Higher-Risk Myelodysplastic Neoplasms or Oligoblastic Acute Myeloid Leukemia: Results of the Randomized Phase 2 PALOMA Study2026 Clinical Lymphoma Myeloma & Leukemia conference-abstract Medicine Acute Myeloid Leukemia Research
Uwe Platzbecker, Martina Crysandt, Martin Kaufmann, Andreas Rank, Christoph Röllig, Hartmut Döhner, +30 more
0citations -
Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY ‐1 and MOMENTUM Trials2026 European Journal Of Haematology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Francesca Palandri, Casey Lee O'Connell, Pankit J. Vachhani, Donal P. McLornan, Steffen Koschmieder, Juan Carlos Hernández‐Boluda, +6 more
0citations -
The implication of TET1, miR-200 and miR-494 expression with tumor formation in colorectal cancer: through targeting WNT signaling2024 Research Square preprint Biochemistry, Genetics and Molecular Biology MicroRNA in disease regulation Open access
Raziye Tajali, Neda Zali, Fatemeh Naderi Noukabadi, Morteza Valinezhad, Farnaz Ghasemian, Makan Cheraghpour, +2 more
0citations -
DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy
Olga Grishina, Claudia Schmoor, Caroline Sellner, Björn W. Hackanson, Jan‐Henrik Mikesch, Iordanis Deligiannis, +28 more
0citations -
Transplant Outcomes for Acute Myeloid Leukemia or Myelodysplastic Syndromes Secondary to Acquired Aplastic Anemia or Paroxysmal Nocturnal Hemoglobinuria: A Report from the EBMT Severe Aplastic Anemia Working Party
Pedro Henrique Prata, Dirk‐Jan Eikema, Brian Piepenbroek, Austin Gladston Kulasekararaj, Beatrice Drexler, Jennifer M.L. Tjon, +19 more
2citations -
Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial2020 Clinical & Translational Immunology article Immunology and Microbiology Immunotherapy and Immune Responses Open access
Felix Sebastian Lichtenegger, Frauke M. Schnorfeil, Maurine Rothe, Katrin Deiser, Torben Altmann, Veit Bücklein, +15 more
39citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Ruben A. Mesa, Rami S. Komrokji, Steffen Koschmieder, +10 more
8citations -
Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT2022 Bone Marrow Transplantation article Medicine Hematopoietic Stem Cell Transplantation Open access
Christian Koenecke, Dirk‐Jan Eikema, Sheree Hazelaar, Thomas A. Schroeder, Victoria T. Potter, Nicolaus Martin Kröger, +19 more
5citations -
MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
2citations -
P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +11 more
1citations -
Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelodysplastic Neoplasms Allografted with an Unrelated Donor: A Registry Study of the Chronic Malignancies Working Party of the EBMT
Yves Chalandon, Dirk‐Jan Eikema, Ivan Moiseev, Fabio Ciceri, Linda Köster, Jan Vydra, +16 more
1citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
1citations -
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria - a Study on Behalf of Cmwp and Saawp of the EBMT
Joanna Ewa Drozd-Sokolowska, Joe Tuffnell, Linda Köster, Uwe Platzbecker, Grzegorz Helbig, Pavel Jindra, +20 more
0citations